Compounded Tirzepatide

In the SURMOUNT-1 trial published in The New England Journal of Medicine (Jastreboff et al., 2022), participants on weekly tirzepatide 15 mg lost an average of 20.9% of body weight at 72 weeks versus 3.1% on placebo. Most patients see meaningful changes after 8–12 weeks as the dose titrates up. Individual results vary based on dose, adherence, diet, and physical activity.

Nausea is most common in the first 1–2 weeks after each dose increase. Eat smaller meals, avoid greasy or very rich foods, stay hydrated, and stop eating at the first sign of fullness. Most GI side effects resolve within two weeks. If nausea is severe, message your care team — your doctor can hold the next dose increase or use a longer titration interval.

The active molecule (tirzepatide) is identical. Branded Zepbound and Mounjaro are manufactured in fixed-dose injector pens by Eli Lilly. Compounded tirzepatide is prepared by 503A pharmacies under individualized prescription, which allows flexible dosing your doctor can tune outside the standard pen strengths. Compounded eligibility is verified by your doctor based on clinical need.

If you miss a dose by fewer than 4 days, take it as soon as you remember and resume your normal weekly schedule. If more than 4 days have passed, skip the missed dose and resume at your next scheduled day. Never double-dose. Message your care team if you are unsure.

Yes — many patients transition to tirzepatide when semaglutide weight loss plateaus or side effects are intolerable. Your doctor will typically restart at 2.5 mg tirzepatide regardless of your prior semaglutide dose, since the molecules are not directly equivalent and the GIP component requires its own tolerance build.

Yes. Baseline labs (metabolic panel, HbA1c, lipid panel, thyroid panel, lipase) are reviewed by your prescribing doctor before a prescription is issued. If you have recent labs (within 12 months), you can upload them; otherwise we coordinate at-home or in-network draws.

Published data (SURMOUNT-4 trial) show most patients regain a meaningful portion of lost weight after discontinuation. Long-term success typically involves continued treatment, transition to a maintenance dose, or a structured lifestyle plan — discussed with your doctor toward the end of your active titration.

Compounded tirzepatide is typically not covered by commercial insurance. Most patients use HSA or FSA funds, which are eligible for prescribed weight-management medication. Branded Zepbound may be covered with prior authorization — your care team can help you check eligibility and compare costs.